• Moderna raised its 2026 revenue growth forecast to 15-25% from up to 10% versus 2025.
• Year-end cash and investments are expected at approximately $8.1 billion to $8.3 billion, previously $4.7 billion to $5.2 billion.
• The higher cash outlook reflects strong operational execution and proceeds from a $3 billion convertible notes financing.
• Third-quarter revenue rose 29% to $1.3 billion, with the business turning a profit.
• Quarterly cash costs fell 10% to $1 billion; full-year costs are now expected to be lower than previously forecast.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.